Meeting
2014 ASCO Annual Meeting
A randomized, double‑blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
Presenter
Patrick Y. Wen, MD
Dana-Farber Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2005)
DOI
10.1200/jco.2014.32.15_suppl.2005
Abstract #
2005
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.
Speaker: Antoine F Carpentier
Videos & Slides
2021 ASCO Annual Meeting
Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.
Speaker: Lukas Rob, MD, PhD
Videos & Slides
2012 ASCO Annual Meeting
Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
Speaker: Surasak Phuphanich, MD
Videos & Slides
2023 ASCO Annual Meeting
Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.
Speaker: Sujay A. Vora, MD